Option chain shows key data for RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd.'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd..

RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd. (OTC:RUFIF) Stock, Option Chain

RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd.

Macro Economic Events

News

Politics

Economics

General

U.S. House Speaker Johnson Says We Have A Unified Agreement Among Republicans To Move Forward On Spending Deal; We Will Not Have A Government Shutdown

<p><strong>BlackBerry Ltd</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) stock surged upwards on Friday. The company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42606549/blackberry-beats-q3-earnings-estimates-but-soft-guidance-keeps-shares-in-check" rel="noreferrer noopener">third-quarter results</a> after the market closed on Thursday.</p>
<p>BlackBerry reported quarterly revenue of $143.00 million, missing the analyst consensus estimate of $161.49 million. The adjusted EPS was $0.02, beating analyst&nbsp;estimates.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42529245/trump-and-netflix-boss-sarandos-set-for-high-stakes-mar-a-lago-meeting" rel="noreferrer noopener">Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting</a></strong></p>
<p>BlackBerry expects fourth-quarter revenue of $126.00 million &#8211; $135.00 million, versus estimates of $150.08 million. It expects adjusted EPS of $(0.01) &#8211; $0.01. Analysts rerated the stock after the quarterly print.</p>
<p><strong>RBC Capital</strong> analyst Paul Treiber reiterated BlackBerry with a Sector Perform and a <a target="_blank" href="https://www.benzinga.com/quote/BB/analyst-ratings" rel="noreferrer noopener">$3.25&nbsp;price target</a>.</p>
<p>BlackBerry&#8217;s third quarter marks its first quarter of financials without Cylance. The quarter exceeded Treiber&#8217;s estimates, though fourth-quarter guidance was short of his expectations.</p>
<p>Excluding Cylance (discontinued operations), third-quarter revenue was $143 million (-7% year-on-year), above Treiber&#8217;s estimated $128 million. All three revenue lines exceeded the analyst&#8217;s expectations: IoT ($62 million versus RBC and consensus at $58 million and $59 million), Secure Communications ($74 million versus RBC at $66 million), and Licensing ($7 million versus RBC and consensus at $4 million). Due to higher revenue, adjusted EBITDA was $35 million, above RBC at $13 million.</p>
<p>The fourth-quarter revenue guidance short of RBC. It calls for $126 million &#8211; $135 million in revenue, below RBC&#8217;s estimate of $138 million. The shortfall stems from Secure Communications ($62 million &#8211; $66 million versus RBC at $71 million). IoT guidance for $60 million &#8211; $65 million bracketed RBC estimate ($64 million). The mid-point of adjusted EBITDA guidance for $10 million &#8211; $20 million missed the RBC estimate of $19 million.</p>
<p>BlackBerry is now profitable and operating cash flow positive. However, Treiber noted that the valuation will likely remain discounted below that of peers pending improved IoT growth (fourth-quarter guidance calls for IoT revenue to be down 5% year-on-year at the mid-point).</p>
<p>BlackBerry is trading at a discounted valuation of 3.0 times NTM Enterprise Value/Sales.</p>
<p>Treiber noted that BlackBerry&#8217;s valuation will likely remain discounted, pending strengthening IoT growth and realizing improved profitability. The price target includes the $120 million cash proceeds from the sale of Cylance and values Secure Communications at 6.0 times calendar 2025 Enterprise Value/EBITDA (unchanged) and the IoT business at 6.1 times calendar 2025 Enterprise Value/ Sales (unchanged).</p>
<p><strong>Price Action:</strong> BB stock is up 23.5% at $3.679 at last check Friday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/tech/24/12/42536593/verizon-teams-up-with-nvidia-to-power-ai-apps-over-private-5g-networks" target="_blank" rel="noreferrer noopener">Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Trading Ideas

BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst

<p><strong>Oppenheimer </strong>initiated coverage on <strong>Rhythm Pharmaceuticals Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a developer of treatment for rare obesity disorders.</p>
<p>The pharmaceutical industry&#8217;s focus on weight management is drawing strong investor interest, with Rhythm Pharmaceuticals standing out for targeting rare obesity disorders that standard treatments often fail to address.</p>
<p>The company is steadily growing its business through the global rollout of Imcivree, a drug designed for several<a href="https://www.benzinga.com/pressreleases/24/12/g42284805/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-" target="_blank" rel="noreferrer noopener"> genetic obesity conditions</a>.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com//node/42613036">Novo Nordisk&#8217;s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges</a></strong></p>
<p>Revenue from global sales of IMCIVREE was $33.3 million for the third quarter of 2024, an increase of 14% on a sequential basis, primarily driven by sales for BBS.</p>
<p>In the third quarter of 2024, revenue of $23.3 million, or 70% of product revenue, was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41757397/rhythm-pharmaceuticals-reports-third-quarter-2024-financial-results-and-business-update" rel="noreferrer noopener">generated in the U.S.</a></p>
<p>Oppenheimer is optimistic about its progress in treating hypothalamic obesity, an acquired condition with high development potential, as Phase 3 trial results are expected in the first half of 2025.</p>
<p>Oppenheimer initiated coverage on Rhythm Pharmaceuticals with an Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/RYTM/analyst-ratings" rel="noreferrer noopener">price target of $76</a>.</p>
<p>Rhythm&#8217;s expertise in MC4 biology positions it for long-term success as Imcivree&#8217;s approved uses expand, new pipeline drugs with improved efficacy and convenience advance, and the company enhances its efforts to identify patients with genetic obesity.</p>
<p>The analyst anticipates significant growth opportunities in 2025 and beyond as Rhythm taps into a multi-billion-dollar total addressable market.</p>
<p>The analyst highlights that severe obesity caused by MC4R pathway defects doesn&#8217;t respond well to popular GLP-1 drugs like <strong>Novo Nordisk A/S&#8217;</strong>&nbsp;&nbsp;Wegovy or <strong>Eli Lilly And Co&#8217;s</strong> Zepbound, noting the experts and studies.</p>
<p>The MC4R drug market has little competition. <strong>Palatin Technologies Inc. </strong>markets Vyleesi (bremelanotide) for sexual disorders and is testing it with Zepbound for general obesity, with results expected in early 2025. Palatin is also developing oral MC4R drugs.</p>
<p><strong>Price Action:</strong> RYTM stock is up 1.71% at $56.43 at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42623020/why-innovative-industrial-stock-is-falling-over-20-today" target="_blank" rel="noreferrer noopener">Innovative Industrial Properties Hit By Cannabis Company PharmaCann&#8217;s Rent Default, Stock Plunges</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Biotech

Health Care

Initiation

RYTM

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

WIIM

LTRY

Lottery.Com shares are trading higher after the company announced it received a Nasdaq compliance determination letter.

ENVX

Enovix shares are trading higher after the company announced it shipped its first EX-2M samples to customers manufactured in its Malaysian Fab 2 plant.

<p><strong>Bitcoin&#8217;s </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sell-off on Friday saw prices dip below $93,000, but <strong>Bitwise </strong>CIO <strong>Matt Hougan</strong> argues that the <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42614273/bitcoin-crashes-10-ethereum-xrp-down-18-dogecoin-craters-28-what-is-going-on">current pullback is a &#8220;hiccup&#8221;</a> rather than a trend reversal.</p>
<p>Hougan sees strong underlying factors including <a href="https://www.benzinga.com/news/events/24/11/41992186/could-new-legislation-finally-bring-clarity-to-us-crypto-rules-industry-expert-weighs-in">regulatory tailwinds</a>, <a href="https://www.benzinga.com/24/12/42516240/the-doors-have-been-blown-off-how-bitcoin-etfs-are-reshaping-investment-strategies">institutional adoption</a> and <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41847581/el-salvadors-bitcoin-bet-is-paying-off-heres-how-much-the-country-is-up">Bitcoin purchases by governments</a> as structurally bullish factors for Bitcoin.</p>
<h2 class="wp-block-heading">Crypto&#8217;s Turbulent Friday Trading Session</h2>
<p>The cryptocurrency market experienced a volatile session Friday, triggered by the <a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">Federal Reserve&#8217;s decision</a> to lower its anticipated rate cuts for the coming year.</p>
<p>Bitcoin plummeted from a high of $108,135 to below $92,805, before rebounding slightly, currently trading around $96,950, down 1.2% on the day.</p>
<p><strong>Ethereum </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) also traded down by 1% to $3,430.</p>
<p>This sharp decline mirrored a <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">broader pullback in risk assets</a>, with the S&amp;P 500 dropping 3% and the Russell 2000 Small Cap Index falling 4.4% following the Fed announcement.</p>
<p>The Fed&#8217;s move, while expected in terms of a <a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">25 basis point rate cut</a>, surprised markets with its <a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">reduced forecast</a> for future cuts. It is now projecting only two in 2025, down from four.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42623985/rattled-hawk-tuah-girl-haliey-welch-resurfaces-after-meme-coin-scandal-i-take-this-situation-extremely-seriously">Rattled &#8216;Hawk Tuah Girl&#8217; Haliey Welch Resurfaces After Meme Coin Scandal: &#8216;I Take This Situation Extremely Seriously&#8217;</a></strong></p>
<h2 class="wp-block-heading">The Fed Matters For Crypto — But Other Factors Matter More</h2>
<p>Potentially higher interest rates traditionally pressure risk assets, and this announcement initiated an initial sell-off across the board, Matt Hougan noted in a social media thread earlier in the day.</p>
<p>However, he emphasized that leverage within the crypto market acted as a significant catalyst for the deeper-than-expected decline. </p>
<p>Hougan maintains that the broader bull market trend remains intact — $1.38 billion of liquidated positions in 24 hours notwithstanding.</p>
<p>He claims the Fed is less impactful to the sector than in previous years, and the industry has gained significant internal momentum due to several fundamental shifts.</p>
<p>He points to several key factors supporting the bullish thesis: </p>
<ul>
<li>An imminent pro-crypto regulatory shift in Washington, see Trump&#8217;s appointment of a &#8216;<a href="https://www.benzinga.com/24/12/42356067/venture-capitalist-david-sacks-appointed-as-white-house-ai-crypto-czar-by-trump">crypto czar</a>.&#8217;</li>
<li>Increasing institutional involvement and ETF flows, such as <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42393396/record-week-bitcoin-etfs-net-25-billion-in-inflows-ethereum-etfs-took-in-12-billion">record-breaking spot ETF flows</a>.</li>
<li>Bitcoin acquisitions by governments and corporations — even <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42601193/senator-lummis-introduces-strategic-bitcoin-reserve-proposal">a strategic Bitcoin reserve</a> may be on the table.</li>
<li>Major technological advancements in the programmable blockchain sector (<a href="https://www.benzinga.com/24/12/42443799/merging-systems-tokenization-and-the-path-to-financial-change">tokenization anyone</a>?).</li>
</ul>
<p>In a series of <a href="https://x.com/Matt_Hougan/status/1869627742561649100">tweets</a>, Hougan also highlighted that Bitcoin&#8217;s 10-day exponential moving average (approximately $102,000) remains above its 20-day exponential moving average (around $99,000), which is a traditional bullish indicator for him. </p>
<p>This technical measure has historically been a reliable gauge of market trends and suggests the medium term trend for Bitcoin, despite the volatility, is still positive.</p>
<h2 class="wp-block-heading">What Technical Indicators Are Saying</h2>
<p>According to <strong>James Toledano</strong>, Chief Operating Officer at <strong>Unity Wallet</strong>, &#8220;Profit taking is definitely at play here, with Bitcoin trading volume rising 24% in the last day and Bitcoin ETF outflows hitting a record $672M in 1 day.&#8221; </p>
<p>This shows recent price volatility is not solely attributable to external influences, but internal to the market as well.</p>
<p>&#8220;Many people who invested earlier in the year will have doubled their money and those who invested years ago, made more than they ever dreamt possible,&#8221; he told Benzinga.</p>
<p>Toledano also noted that whilst Bitcoin trading volume is skewed towards selling, altcoins have been subject to significant trading activity.</p>
<p>Ethereum trading volume is up 45% over 24 hours, with 70% of that buying activity.</p>
<p><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), currently up 1% on the day and recovering from a 20% drop earlier in the day, is seeing a similar volume pattern.</p>
<p><strong>BNB </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) is also up 1.3% at $670.</p>
<p>However, <strong>Dogecoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is down 1% and <strong>Shiba Inu </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) down about 5% , hile <strong>SUI </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>) is up 7% at press time.</p>
<p>While reduced liquidity in the upcoming holiday period could lead to increased volatility, Toledano added, the absence of major institutional activity may stabilize prices. </p>
<p>He also pointed out that, based on historic trends, there is no clear pattern at this time of the year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42617815/are-microstrategys-bitcoin-purchases-on-hold-in-january">Are MicroStrategy&#8217;s Bitcoin Purchases On Hold In January?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$DOGE

$ETH

$SHIB

$SUI

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Whipsaw, But These 4 Key Factors Make It A 'Hiccup,' Not A Downturn

Legal

QCOM

U.S. Jury Is Deadlocked On One Of Questions In Arm's Lawsuit Against Qualcomm, But Is Still Deliberating

Lottery.com Receives Compliance Determination Letter From Nasdaq; Shares Spike Higher

<p>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration&nbsp;(FDA) has approved an expanded indication for IMCIVREE&#xAE; (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.</p>
<p>BBS and POMC, PCSK1 and LEPR deficiencies are rare melanocortin-4 receptor (MC4R) pathway diseases with hallmark characteristics that include hyperphagia, or pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, and early-onset obesity. IMCIVREE is the first and only precision medicine to target impairment of the hypothalamic MC4R pathway, a root cause of hyperphagia and obesity due to BBS and POMC, PCSK1 and LEPR deficiencies in adults and children as young as 2 years old in the United States, as well as Europe.</p>


hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases

IIPR

Innovative Industrial Properties shares are trading lower after the company reported a default by Pharmacann on its obligations to pay rent for six of its eleven leases in December.

PODD

Insulet shares are trading higher amid strength in diabetes-related stocks following weight loss data from Novo Nordisk.

<p>During the last three months, 15 analysts shared their evaluations of Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">13</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $18.53, a high estimate of $20.00, and a low estimate of $16.50. Observing a 5.76% increase, the current average has risen from the previous average price target of $17.52. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721259_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Invesco by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.50</td>
<td>$17.50</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$17.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.50</td>
<td>$17.25</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$16.50</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Invesco. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Invesco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Invesco's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Invesco's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Invesco analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Invesco</h2>
<p>Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of October 2024, the firm had $1.792 trillion in assets under management spread among its equity (58% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (10%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's us retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 29% of its AUM sourced from Europe, Africa, and the Middle East (14%) and Asia (15%).</p>
<h3>Invesco: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Invesco's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>5.09%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Invesco's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>3.63%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.52%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Invesco's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.2%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.69</strong>, Invesco adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Invesco Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)

<p>Applied Fundamental Research, a long-term shareholder of FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>), has submitted an open letter to the company's management and its Board of Directors. The letter highlights FIGS' exceptional achievements in transforming the healthcare apparel market, expresses confidence in the company's ability to execute its growth strategy as a public company, and outlines recommendations for defining a clear capital allocation strategy to unlock shareholder value.</p>
<p>Trina Spear and Heather Hasson<br /><br />FIGS, Inc.<br /><br />2834 Colorado Avenue, Suite 100<br /><br />Santa Monica, CA<br /><br />Cc: FIGS Board of Directors</p>
<p>Dear Trina and Heather,</p>
<p>As long-term shareholders, we at Applied Fundamental Research are proud to support FIGS in its mission to serve the critical healthcare workers across our nation - and increasingly around the world- by empowering them to feel and perform at their best.</p>
<p>Under your leadership, the company has transformed an outdated and stagnant market for healthcare apparel and built a powerful brand that celebrates the contributions of these <i>Awesome Humans</i>. You got here by making bold bets, igniting an entrepreneurial spirit and executing against your vision for elevating how people show up to work.</p>
<p>We are confident that the company is pursuing the right strategy to reignite revenue growth and improve margins over the coming years. As inventory levels normalize and today's innovations bring growth, our recent investments in fulfillment infrastructure will become fully absorbed, creating strong cash flow growth.</p>
<p>Over the past two years, we have seen the team achieve noteworthy milestones that have set the foundation for continued success:</p>
<ul>
<li>Growing Net Active Customer count by over half a million consumers</li>
<li>Managing a bloated inventory balance with discipline, preserving brand integrity without resorting to outsized discounting</li>
<li>Deepening the leadership bench by attracting talented and experienced new hires</li>
<li>Renewing innovation and storytelling through the Extremes campaign and the creative Olympic sponsorship</li>
</ul>
<p>With this progress in mind, we strongly support the Board and management team in rejecting any acquisition offers that do not fully reflect the company's current and potential value. FIGS' exceptional brand equity, pristine balance sheet, and multiple growth vectors within the expansive global marketplace for healthcare apparel leaves the company well positioned for sustained growth and long-term value creation. With laser focus on execution, we believe you and the FIGS team can drive meaningful value for all stakeholders.</p>


Management

FIGS

Applied Fundamental Research Issues Open Letter To FIGS Management And Its Board Of Directors Outlining Recommendations For Defining A Clear Capital Allocation Strategy To Unlock Shareholder Value.

<p>Throughout the last three months, 8 analysts have evaluated Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $156.0, with a high estimate of $179.00 and a low estimate of $140.00. This upward trend is evident, with the current average reflecting a 11.43% increase from the previous average price target of $140.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721249_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Jabil by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$179.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jabil. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jabil compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Jabil's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Jabil's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JBL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Jabil analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Jabil</h2>
<p>Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.</p>
<h3>Financial Milestones: Jabil's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Challenges:</strong> Jabil's revenue growth over 3 months faced difficulties. As of 31 August, 2024, the company experienced a decline of approximately <strong>-17.66%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Jabil's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.98%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Jabil's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.88%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Jabil's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.79%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.88</strong>, caution is advised due to increased financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 8 Analyst Ratings Have To Say About Jabil

<p>In the last three months, 6 analysts have published ratings on SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for SEI Inv, presenting an average target of $79.67, a high estimate of $86.00, and a low estimate of $74.00. Observing a 5.76% increase, the current average has risen from the previous average price target of $75.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721239_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of SEI Inv by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$86.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SEI Inv. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of SEI Inv compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of SEI Inv's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of SEI Inv's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SEIC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on SEI Inv analyst ratings.</strong></a></p>
<h2>All You Need to Know About SEI Inv</h2>
<p>SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $99 billion in assets under management. As of December 2023, SEI (including LSV) manages, administers, or advises about $1.4 trillion in assets.</p>
<h3>Financial Insights: SEI Inv</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, SEI Inv showcased positive performance, achieving a revenue growth rate of <strong>12.72%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> SEI Inv's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>28.82%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> SEI Inv's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.73%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> SEI Inv's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.94%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> SEI Inv's debt-to-equity ratio is below the industry average. With a ratio of <b>0.01</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SEIC

SEI Inv Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

<p>Financial giants have made a conspicuous bullish move on Reddit. Our analysis of options history for Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) revealed 28 unusual trades.</p>
<p>Delving into the details, we found 35% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $479,236, and 24 were calls, valued at $4,050,700.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $115.0 to $260.0 for Reddit during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Reddit options trades today is 714.32 with a total volume of 4,092.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Reddit's big money trades within a strike price range of $115.0 to $260.0 over the last 30 days.</p>
<h3>Reddit 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721236_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$45.55</td>
<td>$42.85</td>
<td>$44.5</td>
<td>$260.00</td>
<td>$1.7M</td>
<td>7</td>
<td align="right">400</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$46.85</td>
<td>$44.0</td>
<td>$45.25</td>
<td>$180.00</td>
<td>$452.5K</td>
<td>1.6K</td>
<td align="right">103</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.6</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$190.00</td>
<td>$324.5K</td>
<td>5.6K</td>
<td align="right">661</td>
</tr>
<tr>
<td>RDDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$66.45</td>
<td>$65.1</td>
<td>$65.1</td>
<td>$200.00</td>
<td>$240.8K</td>
<td>6</td>
<td align="right">38</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.45</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$185.00</td>
<td>$182.5K</td>
<td>1.5K</td>
<td align="right">279</td>
</tr>
</tbody>
</table>
</p>
<h3>About Reddit</h3>
<p>Reddit Inc is engaged in providing internet content. The company provides online services that include gaming, sports, business, crypto, television and others.</p>
<p>After a thorough review of the options trading surrounding Reddit, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Reddit</h3>
<ul>
<li>With a trading volume of 3,183,179, the price of RDDT is up by 4.98%, reaching $171.87.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 95 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Reddit</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $187.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Overweight with a revised price target of $200.<br />
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Overweight with a new price target of $206.<br />
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $210.<br />
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Reddit, targeting a price of $160.<br />
&#x2A; An analyst from JMP Securities has decided to maintain their Market Outperform rating on Reddit, which currently sits at a price target of $160. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Reddit, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

RDDT

What the Options Market Tells Us About Reddit

<p>Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.2, a high estimate of $56.00, and a low estimate of $40.00. This upward trend is apparent, with the current average reflecting a 5.47% increase from the previous average price target of $44.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721232_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Dianthus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dianthus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DNTH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dianthus Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Dianthus Therapeutics's Background</h2>
<p>Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.</p>
<h3>Dianthus Therapeutics's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Dianthus Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>135.06%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Dianthus Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>-1159.02%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Dianthus Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-7.23%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dianthus Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-6.96%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Dianthus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.0</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DNTH

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>MicroStrategy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MSTR, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 104 uncommon options trades for MicroStrategy.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 32% bullish and 35%, bearish.</p>
<p>Out of all of the special options we uncovered, 42 are puts, for a total amount of $3,898,859, and 62 are calls, for a total amount of $5,104,105.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $0.5 and $930.0 for MicroStrategy, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for MicroStrategy options trades today is 2361.91 with a total volume of 150,336.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for MicroStrategy's big money trades within a strike price range of $0.5 to $930.0 over the last 30 days.</p>
<h3>MicroStrategy Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721231_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$31.4</td>
<td>$30.65</td>
<td>$30.68</td>
<td>$370.00</td>
<td>$693.3K</td>
<td>1.9K</td>
<td align="right">61</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$54.5</td>
<td>$52.85</td>
<td>$53.72</td>
<td>$405.00</td>
<td>$370.3K</td>
<td>586</td>
<td align="right">239</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$52.0</td>
<td>$50.45</td>
<td>$51.22</td>
<td>$402.50</td>
<td>$353.1K</td>
<td>536</td>
<td align="right">221</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$33.6</td>
<td>$32.7</td>
<td>$33.25</td>
<td>$365.00</td>
<td>$332.5K</td>
<td>563</td>
<td align="right">836</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$102.65</td>
<td>$102.45</td>
<td>$102.65</td>
<td>$330.00</td>
<td>$277.1K</td>
<td>53</td>
<td align="right">47</td>
</tr>
</tbody>
</table>
</p>
<h3>About MicroStrategy</h3>
<p>MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.</p>
<p>Following our analysis of the options activities associated with MicroStrategy, we pivot to a closer look at the company's own performance.</p>
<h3>MicroStrategy's Current Market Status</h3>
<ul>
<li>With a trading volume of 18,961,668, the price of MSTR is up by 7.08%, reaching $349.56.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 46 days from now.</li>
</ul>
<h3>What The Experts Say On MicroStrategy</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $562.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from BTIG persists with their Buy rating on MicroStrategy, maintaining a target price of $570.<br />
&#x2A; Maintaining their stance, an analyst from Bernstein continues to hold a Outperform rating for MicroStrategy, targeting a price of $600.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for MicroStrategy, targeting a price of $515.<br />
&#x2A; In a cautious move, an analyst from Bernstein downgraded its rating to Outperform, setting a price target of $600.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for MicroStrategy, targeting a price of $525. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MicroStrategy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


MSTR

A Closer Look at MicroStrategy's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bearish approach towards Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RIOT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 19 extraordinary options activities for Riot Platforms. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 31% leaning bullish and 63% bearish. Among these notable options, 2 are puts, totaling $61,379, and 17 are calls, amounting to $841,100.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $25.0 for Riot Platforms during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Riot Platforms options trades today is 7584.62 with a total volume of 20,124.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Riot Platforms's big money trades within a strike price range of $9.0 to $25.0 over the last 30 days.</p>
<h3>Riot Platforms Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721226_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.82</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$20.00</td>
<td>$70.0K</td>
<td>16.1K</td>
<td>3.3K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.86</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$20.00</td>
<td>$70.0K</td>
<td>16.1K</td>
<td>2.8K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.83</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$20.00</td>
<td>$70.0K</td>
<td>16.1K</td>
<td>1.8K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.84</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$20.00</td>
<td>$70.0K</td>
<td>16.1K</td>
<td>1.5K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.86</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$20.00</td>
<td>$69.7K</td>
<td>16.1K</td>
<td>2.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Riot Platforms</h3>
<p>Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.</p>
<p>Following our analysis of the options activities associated with Riot Platforms, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Riot Platforms</h3>
<ul>
<li>Currently trading with a volume of 18,478,271, the RIOT's price is up by 2.28%, now at $11.45. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Riot Platforms, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


RIOT

A Closer Look at Riot Platforms's Options Market Dynamics

<p>7 analysts have expressed a variety of opinions on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $151.86, a high estimate of $190.00, and a low estimate of $114.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.5%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734721222_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$114.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Neurocrine Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Neurocrine Biosciences analyst ratings.</strong></a></p>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
<p>Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.</p>
<h3>Financial Milestones: Neurocrine Biosciences's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Neurocrine Biosciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>24.72%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Neurocrine Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>20.86%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.97%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.8%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd.

RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd. (RUFIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga